Literature DB >> 577895

Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection.

W A Bleyer, R L Dedrick.   

Abstract

Cerebrospinal fluid (CSF) and plasma methotrexate (MTX) concentrations were measured in 76 children and adults who received intrathecal MTX, 12 mg/m2 body surface area, without developing symptoms of lumbar puncture syndrome or drug-induced neurotoxicity. After an initial rapid redistribution of the injected drug, the mean antifolate value in the lumbar CSF declined in a biphasic manner with half-lives of 4.5 and 14 hours. In the plasma the mean MTX concentration reached a peak of 2 X 10(-7) M between 3 and 12 hours after injection and decreased biexponentially thereafter with half-lives of 5.5 and 24 hours. Pharmacokinetic analysis suggested that the predominant mode of MTX transfer from the central nervous system to the systemic circulation is bulk flow absorption of CSF with entrained drug. The two phases of disappearance from the lumbar CSF appear to result from interaction of the convective transport and diffusion between the CSF and brain extracellular fluid (and perhaps some intracellular sites).

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 577895

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  20 in total

Review 1.  Intrathecal drug administration. Present use and future trends.

Authors:  J S Kroin
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 2.  Pharmacology of drugs formulated with DepoFoam: a sustained release drug delivery system for parenteral administration using multivesicular liposome technology.

Authors:  Martin S Angst; David R Drover
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Neoplastic meningitis resulting from hematological malignancies: pharmacokinetic considerations and maximizing outcome.

Authors:  Jai Grewal; Marlon Saria; Harpreet K Grewal; Santosh Kesari
Journal:  Clin Investig (Lond)       Date:  2011-10

Review 4.  Clinical pharmacokinetics of cerebrospinal fluid.

Authors:  M Bonati; J Kanto; G Tognoni
Journal:  Clin Pharmacokinet       Date:  1982 Jul-Aug       Impact factor: 6.447

Review 5.  Antineoplastic drugs: clinical pharmacology and therapeutic use.

Authors:  R A Bender; L A Zwelling; J H Doroshow; G Y Locker; K R Hande; D S Murinson; M Cohen; C E Myers; B A Chabner
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

6.  Probenecid inhibition of methotrexate excretion from cerebrospinal fluid in dogs.

Authors:  A Ramu; D Glaubiger; N P Ramu; N Eldridge; T F Blaschke
Journal:  J Pharmacokinet Biopharm       Date:  1978-10

7.  Dosage and the pharmacokinetics of cytotoxic drugs.

Authors:  J R Trounce
Journal:  Br J Clin Pharmacol       Date:  1979-09       Impact factor: 4.335

8.  Cytostatic treatment of meningeal blastoses.

Authors:  P Engelhardt; R Lorenz
Journal:  J Neurol       Date:  1979-01-05       Impact factor: 4.849

9.  Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions.

Authors:  S B Howell; B B Chu; W E Wung; B M Metha; J Mendelsohn
Journal:  J Clin Invest       Date:  1981-04       Impact factor: 14.808

10.  Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors.

Authors:  S D Baker; R L Heideman; W R Crom; J F Kuttesch; A Gajjar; C F Stewart
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.